碧桂園(02007.HK)旗下碧桂園地產七隻境內債展期方案獲通過
碧桂園(02007.HK)旗下碧桂園地產集團公布,於9月就「H19碧地3」、「H20碧地3」、「H20碧地4」、「H1碧地01」、「H1碧地02」、「H1碧地03」及「H1碧地04」共7筆存續公司債券展期事項召開債券持有人會議,截至9月12日,該七隻境內債的展期方案均已獲得債券持有人會議表決通過。
公司表示,上述七隻境內債完成展期,將有效緩解流動資金壓力,有利於改善整體財務狀況,穩定生產經營,未來將積極履行償債義務,重回良性發展軌道。
該七隻展期債券以及「22碧地02」和「22碧地03」將繼續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.